OCGN Stock Chart & Stats
$21.47
-$0.93(-4.15%)
―
--
Day’s Range― - ―
52-Week Range$14.44 - $45.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)232.00
Market Cap
$7.16B
Enterprise Value$594.30
Total Cash (Recent Filing)$31.86M
Total Debt (Recent Filing)$33.30M
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Jul 31, 2026EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding338,521,850
10 Day Avg. Volume168
30 Day Avg. Volume232
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $14.44 and its highest was $45.50 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $7.16B.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Jul 31, 2026 which is in 6 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on May 05, 2026. The company reported -$1.051 earnings per share for the quarter, missing the consensus estimate of -$0.893 by -$0.158.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.95.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 338,521,850 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$1.051 in its last earnings report, missing expectations of -$0.893. Following the earnings report the stock price went down -17.64%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in MX:OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.